Partner Rare’s team of seasoned professionals are more than just consultants; they are pioneering architects in the rare disease landscape. With deep expertise, extensive experience, and unparalleled connections, we understand the intricate challenges you face and navigate them with innovative and effective strategies.
FOUNDER / CEO: PARTNER RARE
San Godhania
A seasoned entrepreneur and global leader with over 20 years of experience in the biopharmaceutical industry, San has consistently demonstrated an unwavering commitment to improving the lives of patients with rare disorders. From his early days to his current role as a senior leader in the industry, San has consistently showcased his ability to think outside the box, accomplish large projects, and lead with an entrepreneurial spirit. His expertise in expanded access programs has been instrumental in ensuring that patients with unmet medical needs have access to life-saving therapies before full regulatory approval. Additionally, he has played a pivotal role in developing strategic advisory services that empower pharmaceutical and biotechnology companies to navigate the complexities of the rare disease landscape.
Throughout his career, San has consistently demonstrated his ability to lead complex projects and achieve exceptional results. He is a proven strategist with a deep understanding of the rare disease market. His entrepreneurial spirit has been instrumental in the development of innovative solutions that are making a real difference in the lives of patients with rare disorders.
A visionary leader who is shaping the future of rare disease therapeutics. His passion, expertise, and entrepreneurial spirit are driving positive change for patients worldwide. His career trajectory exemplifies his dedication to the rare disease community and his commitment to finding innovative solutions to the challenges of developing and commercializing therapies for these often overlooked patient populations.
Principal Advisor / Consultant
Regulatory / Strategic / Licensing & Business Development / Inward Finance / Clinical /
Government Affairs / Policy
Prof Trevor M Jones | CBE FMedSci
Chairman, Drug Discovery Company, e-Therapeutics plc, Director, Techimmune LLC, Ascension Healthcare plc. Visiting Professor, Institute of Pharmaceutical Science, King’s College London
Professor Trevor Jones is a highly accomplished pharmaceutical and biotechnology industry leader with an extensive and distinguished career spanning over four decades. He is currently Chairman of the Drug Discovery Company, e-Therapeutics plc, and a Director of Techimmune LLC, a California-based company developing a pan-coronavirus vaccine, and Ascension Healthcare plc, a London-based biotech developing products for Haemophilia.
Professor Jones’s expertise extends across the entire pharmaceutical value chain, from early-stage research and development to regulatory affairs and commercialization. He has held senior positions at some of the world’s leading pharmaceutical companies, including Allergan Inc. (USA), where he served as Director, and The Wellcome Foundation, where he was R&D Director. He also served as Director General of the Association of the British Pharmaceutical Industry (ABPI).
A testament to his exceptional contributions to the pharmaceutical industry, Professor Jones has been honoured with honorary degrees and Gold Medals from eight universities. He is a recognized expert in malaria research and was a founding member of the Medicines for Malaria Venture (MMV).
Professor Jones’s commitment to public service is evident in his numerous appointments to government advisory bodies. He has served as a member of The UK Government Regulatory Agency, The Medicines Commission, and the UK Government Advisory Group on Genetics Research. He was also a member of the Wales Government, Bevan Commission on Health, a Commissioner at The World Health Organisation (WHO), and an advisor to the Government of the Netherlands TiPharma Board on Life Science. Additionally, he served as a member of the EU Commission IMI Scientific Advisory Board.
Professor Jones’s deep understanding of the pharmaceutical and biotechnology industries, coupled with his unwavering dedication to advancing healthcare, makes him an invaluable asset to any organization seeking to navigate the complex and dynamic world of pharmaceutical development.
Principal Advisor / Consultant
Regulatory / Strategic / Licensing & Business Development / Inward Finance / Clinical / Government Affairs / Policy
Prof Trevor M Jones | CBE FMedSci
Chairman, Drug Discovery Company, e-Therapeutics plc, Director, Techimmune LLC, Ascension Healthcare plc. Visiting Professor, Institute of Pharmaceutical Science, King’s College London
Professor Trevor Jones is a highly accomplished pharmaceutical and biotechnology industry leader with an extensive and distinguished career spanning over four decades. He is currently Chairman of the Drug Discovery Company, e-Therapeutics plc, and a Director of Techimmune LLC, a California-based company developing a pan-coronavirus vaccine, and Ascension Healthcare plc, a London-based biotech developing products for Haemophilia.
Professor Jones’s expertise extends across the entire pharmaceutical value chain, from early-stage research and development to regulatory affairs and commercialization. He has held senior positions at some of the world’s leading pharmaceutical companies, including Allergan Inc. (USA), where he served as Director, and The Wellcome Foundation, where he was R&D Director. He also served as Director General of the Association of the British Pharmaceutical Industry (ABPI).
A testament to his exceptional contributions to the pharmaceutical industry, Professor Jones has been honoured with honorary degrees and Gold Medals from eight universities. He is a recognized expert in malaria research and was a founding member of the Medicines for Malaria Venture (MMV).
Professor Jones’s commitment to public service is evident in his numerous appointments to government advisory bodies. He has served as a member of The UK Government Regulatory Agency, The Medicines Commission, and the UK Government Advisory Group on Genetics Research. He was also a member of the Wales Government, Bevan Commission on Health, a Commissioner at The World Health Organisation (WHO), and an advisor to the Government of the Netherlands TiPharma Board on Life Science. Additionally, he served as a member of the EU Commission IMI Scientific Advisory Board.
Professor Jones’s deep understanding of the pharmaceutical and biotechnology industries, coupled with his unwavering dedication to advancing healthcare, makes him an invaluable asset to any organization seeking to navigate the complex and dynamic world of pharmaceutical development.
Principal Advisor / Consultant: Legal
Sita Schubert
Sita Schubert is a seasoned legal and business executive with a passion for innovation and patient advocacy. She brings a wealth of experience in the healthcare sector, having served on the board of the pharmaceutical industry and the Pharma Code Association. As an investor, she has a keen eye for promising start-ups and a proven track record of helping them succeed. Her involvement in the cannabis industry since 2016 has been instrumental in bringing medical cannabis companies to the German market.
Prior to her involvement in the cannabis industry, Sita gained extensive experience in the pharmaceutical sector. In addition, and prior to this, she was responsible for a wide range of OTC, OTX, and rare disease drugs for the German, Austrian and Swiss markets for more than a decade. During this time, she developed a deep understanding of strategy, marketing authorization, distribution, and marketing issues.
Sita’s expertise encompasses every aspect of the life science industry. She provides comprehensive consultancy and operational advice for medicinal cannabis, regulatory matters, OTC, Rx-products, and orphan drugs. With her deep understanding of pharmaceutical company management, Sita and her team offer a holistic approach that goes beyond legal counsel to encompass strategic and operational planning.
As a founding member and Secretary General of the European Medical Cannabis Association, Sita is a champion of collaboration and a strong advocate for evidence-based solutions. She believes in fostering dialogue among patient associations, medical professionals, academia, cannabis companies, and pharmaceutical associations to advance the field of medical cannabis and improve patient outcomes.
Sita’s expertise extends to the intricacies of establishing affiliate companies in Germany, a process often fraught with challenges due to its stringent regulations and complex bureaucracy. She possesses a comprehensive understanding of German corporate law, tax requirements, and labour regulations, enabling her to guide clients through the entire setup process seamlessly. Her proficiency in German language and her familiarity with local customs and practices further enhance her ability to connect with German authorities and stakeholders, facilitating a smooth and successful establishment of affiliate companies.
Sita’s unwavering commitment to excellence and her ability to navigate complex challenges make her an invaluable asset to any team. She is a trusted advisor to clients and a respected leader in the healthcare industry, recognized for her expertise in navigating the European market and her ability to guide companies through the establishment of affiliate companies in Germany.
Senior Advisor / Consultant: Strategy / Regulatory / Quality / L&BD
Agnes Kohl
Agnes Kohl is a highly accomplished C-suite leader with over two decades of experience in the rare, orphan, and niche therapies domains. She has a proven track record of successfully managing all critical functions pertaining to both the drug development and commercialization continuum, as well as the Life Cycle Management of rare/orphan and niche therapies.
Agnes’ experience spans multiple C-suite roles, where she has provided strategic direction and leadership at the highest levels. She has substantial international regulatory affairs expertise, with over 300 approvals of therapies in the rare and niche domain. Agnes is also an experienced global team builder, leader, and manager, having fostered cohesive and high-performing teams across diverse functions. She has vast experience in international corporate alliance and portfolio management, and considerable contract management and negotiation expertise.
Agnes possesses a deep understanding of modern tech advancements, particularly in the rare/orphan domain. Her ability to leverage technology effectively enhances the efficiency and effectiveness of her work.
Partner Rare’s exclusive representation of Agnes presents an unparalleled opportunity for companies seeking to expand their rare disorders programs into Europe. With her unparalleled experience, leadership acumen, and technical expertise, Agnes Kohl is poised to drive significant growth and success in this challenging yet rewarding field.
Senior Advisor / Consultant: Strategy / Regulatory / Quality / L&BD
Agnes Kohl
Agnes Kohl is a highly accomplished C-suite leader with over two decades of experience in the rare, orphan, and niche therapies domains. She has a proven track record of successfully managing all critical functions pertaining to both the drug development and commercialization continuum, as well as the Life Cycle Management of rare/orphan and niche therapies.
Kohl’s experience spans multiple C-suite roles, where she has provided strategic direction and leadership at the highest levels. She has substantial international regulatory affairs expertise, with over 300 approvals of therapies in the rare and niche domain. Kohl is also an experienced global team builder, leader, and manager, having fostered cohesive and high-performing teams across diverse functions. She has vast experience in international corporate alliance and portfolio management, and considerable contract management and negotiation expertise.
Kohl possesses a deep understanding of modern tech advancements, particularly in the rare/orphan domain. Her ability to leverage technology effectively enhances the efficiency and effectiveness of her work.
Partner Rare’s exclusive representation of Kohl presents an unparalleled opportunity for companies seeking to expand their rare disorders programs into Europe. With her unparalleled experience, leadership acumen, and technical expertise, Kohl is poised to drive significant growth and success in this challenging yet rewarding field.
Senior Advisor / Consultant: Clinical Trials / Development
Professor Boris Kramer
Professor Boris Kramer, a world-renowned expert in Neonatology, Translational Medicine and Science, Pre-Clinical and Clinical Research, Inflammation/Regeneration, and Cell Therapies, has established himself as a visionary leader in the field of medicine. With over 25 years of experience, Kramer has made significant contributions to the development of innovative therapies for children and adults.
Kramer’s expertise in applying the 3Rs approach to select the most translational in vivo animal and in vitro models for neonatology research has earned him recognition as a leading expert. His commitment to ethical research practices has been instrumental in advancing the understanding of paediatric and neonatal diseases.
Kramer’s success in obtaining two European Orphan Designations for neurological rare diseases, including Frontotemporal Dementia, further highlights his expertise in developing novel therapies for underserved patient populations. His dedication to improving the lives of patients with rare diseases has been recognized through his extensive experience in designing and sponsoring first-in-human phase I and phase II trials of cell therapy.
Kramer’s passion for research is evident in his extensive academic contributions, including over 302 peer-reviewed publications and his supervision of 34 PhD students. His expertise in various medical fields, including preclinical animal models, paediatric and neonatal care, neurology, pulmonology, cardiology, gastroenterology, and cell therapies, has made him a highly sought-after mentor, expert, and collaborator.
Kramer’s leadership and expertise extend to his role as Professor of Experimental Perinatology/Paediatrics and his board certifications in Neonatology and Paediatrics. He is dedicateded to teaching and mentoring the next generation of healthcare professionals and clinical scientists.
Kramer’s extensive experience in organizing and financing industry-sponsored clinical and preclinical research, utilizing both rodent and large mammalian animal models, has made him an invaluable asset to pharmaceutical companies. His expertise in EMA filings (IMPD and ATMP) and his ability to translate preclinical research into clinical outcomes have been instrumental in the development of innovative therapies.
For over a decade, Kramer has provided invaluable industry consulting services, specializing in preclinical research and trial design. His comprehensive expertise encompasses strategic advisory and consulting on small molecules, antibodies, and cell-based therapies, research and protocol development, clinical trial design and execution, EMA regulatory applications and ethics, informed consent, data analysis, clinical study reports, publications, presentations, and conference attendance.
Kramer’s extensive international network in academia and his unparalleled expertise in patient identification further enhance his ability to connect patients with the right clinical trials and accelerate the development of life-saving therapies.
Senior Advisor / Consultant: statistics / market acess / policy / press
Aaron Blocker
Leveraging a master’s degree in biomedical research and extensive experience in data analytics, Aaron has spent the past 14 years consulting with biotech, pharmaceutical companies, and non-profits across the globe, with a particular focus on the US, Europe, and APAC regions. His deep understanding of the regulatory landscape and strong relationships with key organizations like NORD, Eurordis, CAMRARE, and Rare Disease Network allow him to effectively navigate the global rare disease ecosystem.
Living with Hypophosphatasia, his personal experience fuels his commitment to empowering rare disease patients and accelerating access to rare disease therapies. Aaron is a sought-after speaker who cultivates relationships with global patient advocacy groups, fostering connections that inform policy, product development, market access, and launch strategies for rare disease therapies.
Combining academic research with industry experience, Aaron brings a wealth of knowledge in research analytics, insurance, clinical trials, and patient recruitment. Currently, as a Data and Analytics Consultant for a hospital system, he leverages his strong understanding of the healthcare landscape by utilizing SQL within the Epic EMR system for population health data analysis. Aaron is a passionate advocate for patients, with a unique blend of strategic expertise and data-driven analysis.
A patient advocate and thought leader, Aaron champions clinical trials, patient recruitment, and scientific progress. He has a proven ability to build patient communities and collaborate with stakeholders to advance research and accelerate patient access. His expertise in patient engagement empowers healthcare organizations, pharmaceutical companies, and non-profits to prioritize patient-centric care.
As a sought-after speaker, Aaron cultivates relationships with global patient advocacy groups, fostering connections that inform product development, market access, and launch strategies. His ability to bridge the gap between patient experiences and scientific data is invaluable for companies seeking European market approval for rare disease therapies.
Senior Advisor / Consultant: statistics / market acess / policy / press
Aaron Blocker
Leveraging a master’s degree in biomedical research and extensive experience in data analytics, Aaron has spent the past 14 years consulting with biotech, pharmaceutical companies, and non-profits across the globe, with a particular focus on the US, Europe, and APAC regions. His deep understanding of the regulatory landscape and strong relationships with key organizations like NORD, Eurordis, CAMRARE, and Rare Disease Network allow him to effectively navigate the global rare disease ecosystem.
Living with Hypophosphatasia, his personal experience fuels his commitment to empowering rare disease patients and accelerating access to rare disease therapies. Aaron is a sought-after speaker who cultivates relationships with global patient advocacy groups, fostering connections that inform policy, product development, market access, and launch strategies for rare disease therapies.
Combining academic research with industry experience, Aaron brings a wealth of knowledge in research analytics, insurance, clinical trials, and patient recruitment. Currently, as a Data and Analytics Consultant for a hospital system, he leverages his strong understanding of the healthcare landscape by utilizing SQL within the Epic EMR system for population health data analysis. Aaron is a passionate advocate for patients, with a unique blend of strategic expertise and data-driven analysis.
A patient advocate and thought leader, Aaron champions clinical trials, patient recruitment, and scientific progress. He has a proven ability to build patient communities and collaborate with stakeholders to advance research and accelerate patient access. His expertise in patient engagement empowers healthcare organizations, pharmaceutical companies, and non-profits to prioritize patient-centric care.
As a sought-after speaker, Aaron cultivates relationships with global patient advocacy groups, fostering connections that inform product development, market access, and launch strategies. His ability to bridge the gap between patient experiences and scientific data is invaluable for companies seeking European market approval for rare disease therapies.
Senior Advisor / Consultant: Strategy / Regulatory / Commercial
Keith Williams
Keith Williams stands with over two decades of experience shaping the landscape of this intricate and often overlooked domain. His expertise in operational excellence and strategic approaches has been meticulously honed through an extraordinary career that encompasses running his own companies, holding senior positions in esteemed pharmaceutical firms, and providing expert guidance to clients across the globe.
Keith’s profound understanding of rare diseases is rooted in his first hand experience managing and commercializing rare disease products and unlicensed medicines across the UK, Ireland, Nordics, and the EU. His ability to identify and implement unconventional and innovative approaches to market entry and launch has cemented his reputation as a trusted advisor to organizations striving to bring life-altering therapies to patients battling rare disorders.
His extensive experience in general management, commercial, and sales & marketing roles with leading companies like GSK, MSD, LEO, and Lediant Biosciences has further enriched his expertise. This multifaceted experience has equipped him with a comprehensive perspective on the entire drug development and commercialization process, enabling him to provide unparalleled guidance to clients from inception to market triumph.
At Partner Rare, Keith’s leadership and strategic acumen are instrumental in steering clients towards success, empowering them to overcome obstacles and achieve their commercial objectives. His solutions-oriented approach and unwavering dedication to patient well-being render him an invaluable asset to any organization seeking to make a transformative impact on the lives of those affected by rare diseases.
With his unwavering commitment to excellence and his passion for improving the lives of patients, Keith Williams continues to stand as a beacon of hope in the fight against rare diseases. His legacy is one of innovation, collaboration, and a deep-seated belief in the power of science to transform the lives of those touched by these challenging conditions.
Whether you require a single consultation or long-term advisory across a diverse range of areas, our industry-leading team is committed to exceeding your expectations.
Whether you require a single consultation or long-term advisory across a diverse range of areas, our industry-leading team is committed to exceeding your expectations.
Your gateway to successful rare disorder asset commercialization in the European market.
